Brokerages expect Exelixis, Inc. (NASDAQ:EXEL) to post earnings per share of $0.14 for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Exelixis’ earnings. The highest EPS estimate is $0.20 and the lowest is $0.08. Exelixis posted earnings per share of $0.08 during the same quarter last year, which indicates a positive year-over-year growth rate of 75%. The company is scheduled to report its next earnings report on Wednesday, August 1st.
On average, analysts expect that Exelixis will report full-year earnings of $0.85 per share for the current financial year, with EPS estimates ranging from $0.67 to $1.21. For the next fiscal year, analysts anticipate that the business will report earnings of $1.10 per share, with EPS estimates ranging from $0.80 to $2.00. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Exelixis.
Get Exelixis alerts:Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, May 2nd. The biotechnology company reported $0.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.21. The company had revenue of $212.35 million during the quarter, compared to analyst estimates of $146.39 million. Exelixis had a net margin of 43.39% and a return on equity of 77.39%.
Several research analysts have weighed in on EXEL shares. Cann reaffirmed a “buy” rating and set a $40.00 target price on shares of Exelixis in a research note on Thursday, March 8th. Needham & Company LLC lowered their price objective on shares of Exelixis from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, May 11th. William Blair reissued a “buy” rating on shares of Exelixis in a research note on Wednesday, April 11th. TheStreet lowered shares of Exelixis from a “b” rating to a “c+” rating in a research note on Thursday, March 15th. Finally, Stifel Nicolaus lowered their price objective on shares of Exelixis from $30.00 to $29.00 and set a “hold” rating for the company in a research note on Thursday, May 3rd. Two analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $32.80.
Exelixis traded down $0.14, hitting $21.26, during mid-day trading on Monday, Marketbeat.com reports. 45,457 shares of the company were exchanged, compared to its average volume of 5,924,317. The firm has a market cap of $6.35 billion, a PE ratio of 42.00 and a beta of 2.09. Exelixis has a 12-month low of $18.50 and a 12-month high of $32.50.
In related news, VP Patrick J. Haley sold 12,549 shares of the firm’s stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of $22.38, for a total value of $280,846.62. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Michael Morrissey sold 90,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 11th. The shares were sold at an average price of $20.78, for a total transaction of $1,870,200.00. The disclosure for this sale can be found here. In the last three months, insiders sold 610,523 shares of company stock valued at $12,732,688. Insiders own 4.80% of the company’s stock.
Large investors have recently modified their holdings of the stock. American International Group Inc. acquired a new stake in Exelixis in the fourth quarter valued at approximately $208,000. Globeflex Capital L P acquired a new stake in Exelixis in the fourth quarter valued at approximately $246,000. TLP Group LLC acquired a new stake in Exelixis in the first quarter valued at approximately $179,000. Massachusetts Financial Services Co. MA acquired a new stake in Exelixis in the first quarter valued at approximately $215,000. Finally, Washington Trust Bank acquired a new stake in Exelixis in the second quarter valued at approximately $213,000. 77.81% of the stock is currently owned by hedge funds and other institutional investors.
About Exelixis
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Get a free copy of the Zacks research report on Exelixis (EXEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment